Anavex life sciences announces webinar on rett syndrome and anavex®2-73 (blarcamesine) phase 2 data hosted by ladenburg thalmann & co.

New york, dec. 21, 2020 (globe newswire) -- anavex life sciences corp. (“anavex” or the “company”) (nasdaq: avxl), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including alzheimer's disease, parkinson's disease, rett syndrome and other central nervous system (cns) disorders, today announced that ladenburg thalmann & co. will host a webinar at 3:30p.m. eastern time on tuesday, december 22nd, 2020 highlighting rett syndrome and anavex®2-73 (blarcamesine) phase 2 data as part of ladenburg thalmann's lt healthcare symposia series.
AVXL Ratings Summary
AVXL Quant Ranking